Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 5
2005 4
2006 5
2007 4
2009 3
2010 1
2011 2
2012 1
2013 1
2014 1
2015 1
2016 2
2017 1
2018 1
2019 1
2020 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, Makiyama J, Suzuki K, Seki M, Abe K, Imamura K, Watanabe E, Tsuchiya K, Yasumatsu I, Takayama G, Hizukuri Y, Ito K, Taira Y, Nannya Y, Tojo A, Watanabe T, Tsutsumi S, Suzuki Y, Uchimaru K. Yamagishi M, et al. Among authors: ito k. Nature. 2024 Mar;627(8002):221-228. doi: 10.1038/s41586-024-07103-x. Epub 2024 Feb 21. Nature. 2024. PMID: 38383791 Free PMC article.
Intersubject and Intrasubject Variability of Potential Plasma and Urine Metabolite and Protein Biomarkers in Healthy Human Volunteers.
Duisters K, Ogino S, Andou T, Ito K, Akabane T, Harms A, Moerland M, Hashimoto Y, Ando A, Ohtsu Y, Wada N, Yukinaga H, Meulman J, Kobayashi H, Kobayashi N, Suzumura K, Hankemeier T. Duisters K, et al. Among authors: ito k. Clin Pharmacol Ther. 2020 Feb;107(2):397-405. doi: 10.1002/cpt.1606. Epub 2019 Sep 23. Clin Pharmacol Ther. 2020. PMID: 31400148
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R. Natsume A, et al. Among authors: ito k. Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155. Neuro Oncol. 2023. PMID: 35722822 Free PMC article. Clinical Trial.
32 results